argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

Rhea-AI Summary

argenx (Euronext & Nasdaq: ARGX), a global immunology company focused on severe autoimmune diseases, has announced it will host a conference call and audio webcast on Thursday, February 27, 2025, at 2:30 PM CET (8:30 AM ET) to discuss its full year 2024 financial results and provide a fourth quarter business update.

The webcast will be accessible through the Investors section of the argenx website, with a replay available for approximately one year. The company has provided international dial-in numbers for Belgium, France, Netherlands, United Kingdom, United States, Japan, and Switzerland, with access code 3810049 for participants to join the call.

February 20, 2025

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 27, 2025 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2024 financial results and provide a fourth quarter business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

Dial-in numbers:

Belgium           32 800 50 201
France                    33 800 943355
Netherlands           31 20 795 1090
United Kingdom 44 800 358 0970
United States           1 800 715 9871
Japan                    81 3 4578 9081
Switzerland           41 43 210 11 32

Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X (formerly known as Twitter), and Instagram.

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy (US)
aroy@argenx.com

Lynn Elton (EU)
lelton@argenx.com

FAQ

When will argenx (ARGX) report its full year 2024 financial results?

argenx will report its full year 2024 financial results on Thursday, February 27, 2025, at 2:30 PM CET (8:30 AM ET).

How can investors access the argenx (ARGX) Q4 2024 earnings call?

Investors can access the call through the webcast on argenx's website (Investors section) or by using provided international dial-in numbers with access code 3810049.

How long will the argenx (ARGX) Q4 2024 earnings webcast replay be available?

The webcast replay will be available on the argenx website for approximately one year following the presentation.

What topics will be covered in the argenx (ARGX) February 27, 2025 conference call?

The conference call will cover argenx's full year 2024 financial results and provide a fourth quarter business update.